<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915070</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-320708</org_study_id>
    <nct_id>NCT00915070</nct_id>
  </id_info>
  <brief_title>Role of Endothelin-1 in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans</brief_title>
  <official_title>Role of Endothelin-1 in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autoregulation is defined as the ability of a vascular bed to adapt its vascular resistance
      to changes in perfusion pressure. In the eye, several studies have reported that retinal
      blood flow is autoregulated over a wide range of ocular perfusion pressures. The
      investigators could recently show that Endothelin-1 is a key metabolite in the regulation of
      vascular tone in the eye and plays an important role in the blood flow autoregulation of the
      choroidal circulation. However, no data is yet available for the optic nerve head. Thus, the
      present study is designed to test the hypothesis that Endothelin-1 plays also a role in optic
      nerve head blood flow autoregulation.

      Therefore, subjects will perform squatting to increase systemic perfusion pressure during
      administration of either an endothelin A-receptor blocker (BQ-123) or placebo. Optic nerve
      head blood flow will be continuously measured during the procedure to investigate optic nerve
      head autoregulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optic nerve head pressure-flow relationship</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BQ-123</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Physiological saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BQ-123</intervention_name>
    <description>60 mcg/min, infusion period: 60 min</description>
    <arm_group_label>BQ-123</arm_group_label>
    <arm_group_label>Physiological saline solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiological saline solution</intervention_name>
    <description>infusion period 60 minutes</description>
    <arm_group_label>BQ-123</arm_group_label>
    <arm_group_label>Physiological saline solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser Doppler Flowmetry</intervention_name>
    <description>blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow</description>
    <arm_group_label>BQ-123</arm_group_label>
    <arm_group_label>Physiological saline solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Goldmann Applanation Tonometer</intervention_name>
    <description>intraocular pressure measurements</description>
    <arm_group_label>BQ-123</arm_group_label>
    <arm_group_label>Physiological saline solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>squatting</intervention_name>
    <description>subjects will perform squatting for 6 minutes while blood flow measurements</description>
    <arm_group_label>BQ-123</arm_group_label>
    <arm_group_label>Physiological saline solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged between 18 and 35 years, nonsmokers

          -  Men and women will be included in equal parts

          -  Normal findings in the medical history and physical examination unless the
             investigator considers an abnormality to be clinically irrelevant

          -  Normal findings in the laboratory testings unless the investigator considers an
             abnormality to be clinically irrelevant

          -  Normal ophthalmic findings, ametropia less than 3 diopters

        Exclusion Criteria:

          -  Regular use of medication, abuse of alcoholic beverages, participation in a clinical
             trial in the 3 weeks preceding the study

          -  Treatment in the previous 3 weeks with any drug (except intake of oral contraceptives)

          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day

          -  History or presence of gastrointestinal, liver or kidney disease, or other conditions
             known to interfere with distribution, metabolism or excretion of study drugs

          -  Blood donation during the previous 3 weeks

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriele Fuchsjaeger-Mayrl, MD, Univ.Doz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2009</study_first_posted>
  <last_update_submitted>August 9, 2012</last_update_submitted>
  <last_update_submitted_qc>August 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerhard Garhofer</investigator_full_name>
    <investigator_title>Ass.Prof.Priv.Doz.Dr.</investigator_title>
  </responsible_party>
  <keyword>BQ-123</keyword>
  <keyword>Optic Nerve Head Blood Flow</keyword>
  <keyword>Intraocular Pressure</keyword>
  <keyword>Regional Blood Flow</keyword>
  <keyword>Ocular Physiology</keyword>
  <keyword>Optic Disk</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>cyclo(Trp-Asp-Pro-Val-Leu)</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

